Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

11.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

602
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
602
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

649
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
649
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

836
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
836
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

295
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
295

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2023 International Rome consensus for the nomenclature of Sjögren disease.

Nature reviews. Rheumatology·2025
Same author

Emerging treatment for Sjögren's disease: a review of recent phase II and III trials.

Expert opinion on emerging drugs·2023
Same author

Axial Articular Manifestations in Primary Sjögren Syndrome: Have We Been Missing Spondyloarthritis for All This Time?

The Journal of rheumatology·2021
Same author

Treatment of Sjögren's syndrome: current therapy and future directions.

Rheumatology (Oxford, England)·2019
Same author

Standardisation of labial salivary gland biopsies in Sjogren's syndrome: importance for the practicing rheumatologist.

Annals of the rheumatic diseases·2017
Same author

Is salivary gland ultrasonography a useful tool in Sjögren's syndrome?

Rheumatology (Oxford, England)·2016

Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

2.2K

Sjögren Syndrome: Why Do Clinical Trials Fail?

Robert I Fox1, Carla M Fox1

  • 1Rheumatology Clinic, Scripps Memorial Hospital, XiMED Medical Group, 9850 Genesee Avenue, Suite 910, La Jolla, CA 92037, USA.

Rheumatic Diseases Clinics of North America
|July 20, 2016
PubMed
Summary

Sjögren syndrome treatments failed due to focusing on benign symptoms, not severe manifestations. Rituximab shows promise for specific severe Sjögren syndrome cases, suggesting a need for targeted therapeutic approaches.

Keywords:
Benign glandular manifestationsDanger hypothesisDanger-associated molecular patternsExtraglandular manifestationsFunctional circuitKeratoconjunctivitis siccaNeurohypothalamic-immune axisSjögren syndrome

More Related Videos

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

6.2K
A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue
09:42

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue

Published on: June 7, 2017

12.1K

Related Experiment Videos

Last Updated: Mar 17, 2026

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

2.2K
Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

6.2K
A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue
09:42

A Chronic Autoimmune Dry Eye Rat Model with Increase in Effector Memory T Cells in Eyeball Tissue

Published on: June 7, 2017

12.1K

Area of Science:

  • Rheumatology and Immunology
  • Autoimmune Diseases
  • Clinical Trial Design

Background:

  • Sjögren syndrome (SS) presents with diverse glandular and extraglandular symptoms.
  • Current disease-modifying antirheumatic drugs (DMARDs) and biologics have shown limited efficacy in improving benign symptoms, which significantly impact patient quality of life.
  • Previous clinical trials for SS have largely failed to demonstrate significant benefits for the majority of patients.

Purpose of the Study:

  • To analyze the reasons behind the failure of recent double-blind prospective trials for Sjögren syndrome.
  • To evaluate the efficacy of rituximab in specific Sjögren syndrome patient subgroups.
  • To propose future research directions for effectively treating Sjögren syndrome.

Main Methods:

  • Review of double-blind prospective trials of traditional DMARDs and biologics in Sjögren syndrome.
  • Analysis of rituximab's effectiveness in Sjögren syndrome patients with specific severe manifestations.
  • Examination of patient populations and symptom profiles in clinical trial data.

Main Results:

  • Trials failed because they did not adequately address or improve benign symptoms, the primary cause of reduced quality of life in most Sjögren syndrome patients.
  • Rituximab demonstrated effectiveness in Sjögren syndrome patients with specific comorbidities such as mixed cryoglobulinemia, parotid gland swelling, and thrombocytopenia.
  • The limited number of patients with these severe manifestations in FDA approval trials contributed to the overall study failures.

Conclusions:

  • The failure of recent Sjögren syndrome trials highlights the inadequacy of current treatment paradigms for benign symptoms.
  • Rituximab represents a potential therapeutic option for a subset of Sjögren syndrome patients with specific severe extraglandular manifestations.
  • Future research should focus on targeted therapies for distinct Sjögren syndrome phenotypes and prioritize symptom clusters that significantly impair quality of life.